Կանադա - անգլերեն - Health Canada

pfizer canada ulc - neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a; neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b - suspension - 60mcg; 60mcg - neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a 60mcg; neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b 60mcg - vaccines

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - diphtheria crm197 protein, quantity: 16.7 microgram; meningococcal oligosaccharide group a, quantity: 10 microgram - injection, powder for - excipient ingredients: sucrose; monobasic potassium phosphate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - meningococcus a, purified polysaccharides antigen; meningococcus w135, purified polysaccharides antigen; meningococcus y, purified polysaccharides antigen; meningococcus c, purified polysaccharides antigen conjugated -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - meningococcal group c oligosaccharide; meningococcal group w oligosaccharide; meningococcal group y oligosaccharide; meningococcal group a oligosaccharide -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - purified meningococcal polysaccharide group a; purified meningococcal polysaccharide group c; purified meningococcal polysaccharide group y; purified meningococcal polysaccharide group w135 -

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosuppressants - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y.the use of this vaccine should be in accordance with available official recommendations.

Կանադա - անգլերեն - Health Canada

sanofi pasteur limited - meningococcal group a polysaccharide-tetanus toxoid conjugate; meningococcal group c polysaccharide-tetanus toxoid conjugate; meningococcal group y polysaccharide-tetanus toxoid conjugate; meningococcal group w polysaccharide-tetanus toxoid conjugate; tetanus toxoid - solution - 10mcg; 10mcg; 10mcg; 10mcg; 55mcg - meningococcal group a polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group c polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group y polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group w polysaccharide-tetanus toxoid conjugate 10mcg; tetanus toxoid 55mcg - vaccines

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group b factor h binding protein subfamily a 0.12 mg/ml;  ; neisseria meningitidis group b factor h binding protein subfamily b 0.12 mg/ml;   - suspension for injection - 120 mcg/0.5ml - active: neisseria meningitidis group b factor h binding protein subfamily a 0.12 mg/ml   neisseria meningitidis group b factor h binding protein subfamily b 0.12 mg/ml   excipient: aluminium as aluminium phosphate histidine polysorbate 80 sodium chloride water for injection - trumenba is indicated in individuals 10 years and older for active immunisation to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.